Literature DB >> 23275834

From Transplant to Tablets: A paradigm shift in Oncology.

Ikram A Burney1, Mansour S Al-Moundhri.   

Abstract

Year:  2012        PMID: 23275834      PMCID: PMC3523987          DOI: 10.12816/0003163

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


× No keyword cloud information.
  28 in total

Review 1.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 2.  Bone-marrow transplantation (second of two parts).

Authors:  E D Thomas; R Storb; R A Clift; A Fefer; L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-24       Impact factor: 91.245

3.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

4.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

Authors:  B Fisher; P Carbone; S G Economou; R Frelick; A Glass; H Lerner; C Redmond; M Zelen; P Band; D L Katrych; N Wolmark; E R Fisher
Journal:  N Engl J Med       Date:  1975-01-16       Impact factor: 91.245

Review 5.  Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Authors:  G D Demetri
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

6.  Chronic Myeloid Leukaemia: A paradigm for malignancy or just a strange disease?

Authors:  Shaun R McCann
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

7.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

8.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.

Authors:  G Bonadonna; R Zucali; S Monfardini; M De Lena; C Uslenghi
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

9.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

10.  Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.

Authors:  M Horita; E J Andreu; A Benito; C Arbona; C Sanz; I Benet; F Prosper; J L Fernandez-Luna
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

View more
  1 in total

1.  Precision Medicine: Where have we reached and where are we headed?

Authors:  Ikram A Burney; Ritu Lakhtakia
Journal:  Sultan Qaboos Univ Med J       Date:  2017-10-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.